Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03230747 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorTrial completedStudy completion date changed from estimate of Aug 31, 2027 to Aug 20, 2026 · Eligibility criteria expanded, about 32 words · Site details revised at 2 of 9 sitesShow 3 more changesShow less
Study completion date changed from estimate of Aug 31, 2027 to Aug 20, 2026
Eligibility criteria expanded, about 32 words
Site details revised at 2 of 9 sites
MinorCompletion date: Aug 2027 to Aug 31, 2027v15
MinorEnrollment target: 74 to 72v14
Minor4 versionsRe-verified since May 19, 2022, no change to tracked fieldsv10-v13
NotableLead sponsor: [Redacted] to Edwards LifesciencesTrial status: Withheld to Active, Not Recruiting · Primary completion date: Jun 16, 2021 · Completion date: Aug 2027 · 2 morev9Show 5 more changesShow less
Minor7 versionsRe-verified since Aug 24, 2017, no change to tracked fieldsv2-v8
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the safety and functionality of the SAPIEN M3 System in patients with symptomatic, severe MR and will provide guidance for future clinical study designs utilizing the SAPIEN M3 System.